Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805645085> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2805645085 endingPage "e17066" @default.
- W2805645085 startingPage "e17066" @default.
- W2805645085 abstract "e17066 Background: The epidermal growth factor receptor (EGFR) family member-3 (HER3) signaling plays an important role in resistance to (EGFR)-targeted therapy in head and neck squamous cell carcinoma (HNSCC). To better understand the effect of combining an anti-HER3 antibody MM-121/SAR256212 with cetuximab in HNSCC, we studied this drug combination utilizing patient derived xenograft (PDX) models of HNSCC. Methods: Cetuximab resistant HNSCC cell line SCC1-C and its parental cell line SCC1-P were treated with cetuximab, MM121 and their combination. HER3 activation, AKT and ERK signaling pathways were evaluated by western blotting. SRB and colony formation assays were performed to investigate the combined effect of MM121 and cetuximab on cancer cell growth. SCC1-C xenograft and PDX models were carried out to evaluate the efficacy of MM121 and cetuximab combination. Results: Cetuximab induced HER3 activation in cell lines; the combined treatment blocked EGFR and HER3 and inhibited PI3K/AKT and ERK as well as cell growth more effectively compared to each of the antibodies in vitro. Both cetuximab resistant HNSCC xenograft and the PDX models revealed a better efficacy of the combination compared to the single antibodies. In PDX models from patients A(T4aN2c floor of mouth), C(T4aN2b pyriform sinus), and D(T4bN2b retromolar trigone), both cetuximab and the combination inhibited tumor growth (p < 0.001 for both treatments). There was no significant difference between cetuximab and the combination in tumors A and C, but in D, the combination was significantly more effective (p < 0.001). After discontinuation tumors treated with cetuximab recurred in patient A’s PDX, whereas relapse was undetectable in the combination. In patient B’s PDX (T4aN2b of the alveolar ridge), only the combination inhibited tumor growth (p = 0.004) and was more effective than cetuximab (p = 0.032). Conclusions: Dual targeting with of cetuximab and MM-121 was more effective than cetuximab alone in a HNSCC PDX model. Since this model is highly clinically predictive, it provides a compelling rationale for further clinical investigation of this combination in patients with HNSCC who have progressed following cetuximab therapy." @default.
- W2805645085 created "2018-06-13" @default.
- W2805645085 creator A5003855325 @default.
- W2805645085 creator A5010399375 @default.
- W2805645085 creator A5015043790 @default.
- W2805645085 creator A5019077694 @default.
- W2805645085 creator A5022023254 @default.
- W2805645085 creator A5036672833 @default.
- W2805645085 creator A5056136011 @default.
- W2805645085 creator A5059710197 @default.
- W2805645085 creator A5066168392 @default.
- W2805645085 creator A5083126177 @default.
- W2805645085 creator A5083667162 @default.
- W2805645085 creator A5088965012 @default.
- W2805645085 date "2015-05-20" @default.
- W2805645085 modified "2023-09-27" @default.
- W2805645085 title "Dual targeting of EGFR and HER3 with cetuximab and MM-121/SAR256212 in HNSCC patient derived xenograft (PDX) models." @default.
- W2805645085 doi "https://doi.org/10.1200/jco.2015.33.15_suppl.e17066" @default.
- W2805645085 hasPublicationYear "2015" @default.
- W2805645085 type Work @default.
- W2805645085 sameAs 2805645085 @default.
- W2805645085 citedByCount "1" @default.
- W2805645085 countsByYear W28056450852016 @default.
- W2805645085 crossrefType "journal-article" @default.
- W2805645085 hasAuthorship W2805645085A5003855325 @default.
- W2805645085 hasAuthorship W2805645085A5010399375 @default.
- W2805645085 hasAuthorship W2805645085A5015043790 @default.
- W2805645085 hasAuthorship W2805645085A5019077694 @default.
- W2805645085 hasAuthorship W2805645085A5022023254 @default.
- W2805645085 hasAuthorship W2805645085A5036672833 @default.
- W2805645085 hasAuthorship W2805645085A5056136011 @default.
- W2805645085 hasAuthorship W2805645085A5059710197 @default.
- W2805645085 hasAuthorship W2805645085A5066168392 @default.
- W2805645085 hasAuthorship W2805645085A5083126177 @default.
- W2805645085 hasAuthorship W2805645085A5083667162 @default.
- W2805645085 hasAuthorship W2805645085A5088965012 @default.
- W2805645085 hasConcept C121608353 @default.
- W2805645085 hasConcept C126322002 @default.
- W2805645085 hasConcept C143998085 @default.
- W2805645085 hasConcept C2776530083 @default.
- W2805645085 hasConcept C2776833033 @default.
- W2805645085 hasConcept C2777506169 @default.
- W2805645085 hasConcept C2779438470 @default.
- W2805645085 hasConcept C2779998722 @default.
- W2805645085 hasConcept C502942594 @default.
- W2805645085 hasConcept C526805850 @default.
- W2805645085 hasConcept C55493867 @default.
- W2805645085 hasConcept C57074206 @default.
- W2805645085 hasConcept C62478195 @default.
- W2805645085 hasConcept C71924100 @default.
- W2805645085 hasConcept C75217442 @default.
- W2805645085 hasConcept C86554907 @default.
- W2805645085 hasConcept C86803240 @default.
- W2805645085 hasConceptScore W2805645085C121608353 @default.
- W2805645085 hasConceptScore W2805645085C126322002 @default.
- W2805645085 hasConceptScore W2805645085C143998085 @default.
- W2805645085 hasConceptScore W2805645085C2776530083 @default.
- W2805645085 hasConceptScore W2805645085C2776833033 @default.
- W2805645085 hasConceptScore W2805645085C2777506169 @default.
- W2805645085 hasConceptScore W2805645085C2779438470 @default.
- W2805645085 hasConceptScore W2805645085C2779998722 @default.
- W2805645085 hasConceptScore W2805645085C502942594 @default.
- W2805645085 hasConceptScore W2805645085C526805850 @default.
- W2805645085 hasConceptScore W2805645085C55493867 @default.
- W2805645085 hasConceptScore W2805645085C57074206 @default.
- W2805645085 hasConceptScore W2805645085C62478195 @default.
- W2805645085 hasConceptScore W2805645085C71924100 @default.
- W2805645085 hasConceptScore W2805645085C75217442 @default.
- W2805645085 hasConceptScore W2805645085C86554907 @default.
- W2805645085 hasConceptScore W2805645085C86803240 @default.
- W2805645085 hasIssue "15_suppl" @default.
- W2805645085 hasLocation W28056450851 @default.
- W2805645085 hasOpenAccess W2805645085 @default.
- W2805645085 hasPrimaryLocation W28056450851 @default.
- W2805645085 hasRelatedWork W1964368483 @default.
- W2805645085 hasRelatedWork W2000204434 @default.
- W2805645085 hasRelatedWork W2024936926 @default.
- W2805645085 hasRelatedWork W2037602535 @default.
- W2805645085 hasRelatedWork W2062707457 @default.
- W2805645085 hasRelatedWork W2159175023 @default.
- W2805645085 hasRelatedWork W2411566683 @default.
- W2805645085 hasRelatedWork W3159430777 @default.
- W2805645085 hasRelatedWork W4319032158 @default.
- W2805645085 hasRelatedWork W2575240156 @default.
- W2805645085 hasVolume "33" @default.
- W2805645085 isParatext "false" @default.
- W2805645085 isRetracted "false" @default.
- W2805645085 magId "2805645085" @default.
- W2805645085 workType "article" @default.